Barclays’s ARK Genomic Revolution ETF ARKG Stock Holding History

Barclays’s Portfolio ARKG Stock Details ARKG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-160,000	Closed	-$4.6M	–	4851
2024 Q1	$4.6M	Buy	+160,000	New	+$4.81M	﹤0.01%	1918

Other funds holding ARKG

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

State of Wisconsin Investment Board Madison, Wisconsin $43.7B AUM 27.76% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Barclays's ARKG Position: Q4 2025 in Review

Barclays sold out of ARK Genomic Revolution ETF (ARKG) in Q4 2025, closing a stake of 15 shares — an estimated $417 sold.

Barclays first reported a position in ARKG in Q4 2020 and held it in 20 quarters. The position peaked at $7.3M in Q3 2024. 238 funds tracked by Wall St. Rank hold ARKG as of Q4 2025.

Barclays reported no remaining ARK Genomic Revolution ETF position as of Q4 2025 after selling out during the quarter.
Barclays sold 15 ARK Genomic Revolution ETF shares in Q4 2025, an estimated $417.
Barclays first reported a position in ARK Genomic Revolution ETF in Q4 2020 and held it in 20 quarters.
Barclays's ARK Genomic Revolution ETF position peaked at $7.3M in Q3 2024.
238 funds tracked by Wall St. Rank held ARK Genomic Revolution ETF as of Q4 2025.

Based on Barclays's 13F filing for Q4 2025, filed 13 Feb 2026.